Our Stroke Research Group is led by Clinical Professor Neville Knuckey and Adjunct Professor Bruno Meloni. The group’s core focus is to develop neuroprotective treatments to minimise brain damage after a stroke, and other neurological disorders causing brain injury.
After discovering peptides rich in the amino acid arginine are highly neuroprotective and can limit brain damage after a stroke, the team have been working to develop a lead peptide known as ARG-007 as a potential therapy. The therapy would allow us to accomplish our current focus and extend the therapeutic time window for medical interventions to break up the blood clot or to remove the clot in the brain’s blood vessel which caused the stroke, ultimately preserving brain tissue and improving patient outcome. To progress ARG-007 to the clinic, the UWA and Perron Institute ASX listed spin-out company Argenica Therapeutics was established in 2021. In addition, ongoing research is exploring the potential application of ARG-007 as a neuroprotective treatment for other neurological conditions such as neonatal asphyxia, traumatic brain injury and Parkinson’s disease.
- 2018 Neuroscience Eccles Research Award (Prof Neville Knuckey)
- VitalTrace Pty Ltd, Zimmer & Peacock AS, The Trustee for Procept Unit Trust, Perron Institute for NeurologicaL and Translational Science Limited, University of Western Australia, Design & Industry Pty Ltd, Monash University, University of Technology Sydney, including Adam Edwards. CRC-P for "DelivAssure - a novel monitoring device to detect hypoxia during childbirth" (2021-2024)
- Edwards, Rosenow, Meloni, Knuckey. Sir Charles Gairdner Hospital Research Fund for "Pre-clinical assessment of poly-arginine-18 (R18) peptide to reduce brain white matter injury after perinatal hypoxic ischaemic encephalopathy (HIE): An MRI validation study" (2021-2022)
- Meloni, Knuckey. MSWA for "R18D neuroprotective dose response effectiveness when administered alone or with the thrombolytic agent alteplase in an experimental stroke model" (2021)
- Anderton, Meloni, Akkari & Chiba-Falek. Raine Medical Research Foundation Priming Grant for "Investigating a novel class of peptide as a therapeutic for neurodegenerative disorders" (2020-2021)